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-Tocopherol preserves endothelial cell migration
in the presence of cell-oxidized low-density
lipoprotein by inhibiting changes in cell
membrane fluidity
John A. van Aalst, MD,a William Burmeister,b Paul L. Fox, PhD,c and Linda M. Graham, MD,d
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Objective: Endothelial cell (EC) migration is essential for healing areas of arterial injury and angioplasty sites. Iron or
copper-oxidized low-density lipoprotein (oxLDLCu) inhibits EC migration in vitro, but the effect of physiologically
relevant monocyte/macrophage-oxidized LDL (oxLDLcell) is unknown. We postulated that oxLDLcell would inhibit EC
migration and that this inhibition would be reversed by antioxidants.
Methods: The effect of oxLDLCu and oxLDLcell on EC migration was studied by using a razor scrape assay, and migration
was assessed after 24 hours. In addition, ECs were incubated with various antioxidants, including butylated hydroxy-
toluene (BHT), probucol, or -tocopherol, for 1 hour prior to initiation of the scrape assay and application of oxLDL.
Results: Both oxLDLCu and oxLDLcell inhibited migration. The antioxidants did not alter the antimigratory activity of
oxLDLCu, but -tocopherol preserved EC migration in the presence of oxLDLcell. The lack of effect of BHT or probucol
suggested that the effect of -tocopherol resided not in its antioxidant activity but in its membrane-stabilizing properties.
To test this theory, the effect of oxLDL and -tocopherol on relative cell membrane fluidity was assessed by fluorescence
recovery after photobleaching. Both oxLDLCu and oxLDLcell increased relative membrane fluidity. Preincubation with
-tocopherol inhibited the increase in membrane fluidity of ECs incubated in oxLDLcell but not in oxLDLCu.
Conclusions: These studies show that -tocopherol preserves EC migration in oxLDLcell and hastens restoration of the
endothelial monolayer after injury by inhibiting changes in membrane integrity caused by oxLDL. (J Vasc Surg 2004;
39:229-37.)
Clinical Relevance: Recent studies find that vitamin E is not efficacious in the secondary prevention of cardiovascular
events, perhaps because vitamin E does not efficiently block oxidation pathways known to be operative in atherosclerotic
arteries. “Non-antioxidant” properties of vitamin E, however, could be important in the primary prevention of
atherosclerosis and its complications. Our in vitro studies show that -tocopherol can preserve endothelial migration in
the presence of cell-oxidized LDL. This effect might improve the healing of endothelial injuries at sites of arterial repair
or angioplasties, especially in lipid-laden arterial walls.
Endothelial cell (EC) migration is central to many
normal and pathologic processes, including wound heal-
ing, tumor angiogenesis, and restoration of endothelial
integrity after arterial injury. EC migration in vitro is stim-
ulated by growth factors and inhibited by oxidized low-
density lipoprotein (oxLDL) produced by incubation with
iron or copper ions.1,2 Oxidized lipids accumulate in the
atherosclerotic arterial wall and might impair EC migration
in vivo. Delayed re-endothelialization of an arterial injury
or angioplasty site could allow prolonged smooth muscle
cell (SMC) proliferation, resulting in restenosis. In fact,
oxLDL has been implicated as contributing to restenosis
after coronary angioplasty.3 We have shown that products
of lipid oxidation accumulate in prosthetic grafts in vivo,4
but the effect on EC migration onto the graft is not known.
Most in vitro studies use oxLDL generated by incubat-
ing LDL with micromolar concentrations of transition
metal ions, such as iron or copper ions (oxLDLCu). Because
unbound, transition metal ions are not likely to exist in
plasma, where most copper and iron ions are bound to
ceruloplasmin and transferrin, respectively, the applicability
of in vitro EC migration studies to in vivo endothelial repair
is unclear. ECs, SMCs, and monocytes can oxidize LDL,
and cell-modified LDL (oxLDLcell) is more physiologically
relevant than oxLDLCu. Differences in the biochemistry of
cell-mediated and copper-mediated oxLDL have been
identified.5 Compared with oxLDLCu, oxLDLcell is char-
acterized by a slower rate of formation, lower levels of
thiobarbituric acid–reacting substances (TBARSs), limited
inhibition by superoxide dismutase, and the requirement
of nanomolar (rather than micromolar) concentrations
of transition metal ions during the oxidation process.5
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OxLDLcell has many biologic effects that are similar to
oxLDLCu, but the effect of oxLDLcell on EC migration has
not been reported previously. As an initial step in studying
the relevance of inhibition of EC migration by oxLDL, we
tested the ability of LDL oxidized by activated monocytes
to inhibit EC migration. OxLDLcell inhibited EC migra-
tion to a similar degree as oxLDLCu.
Because studies in hypercholesterolemic animals have
suggested that -tocopherol attenuates intimal hyperplasia
and restenosis after balloon injury,6,7 we investigated the
effectiveness of -tocopherol and other chain-breaking an-
tioxidants in preserving EC migration in vitro. Antioxidants
were ineffective in preventing the inhibition of EC migra-
tion by oxLDLCu, but -tocopherol did preserve migration
of ECs incubated in oxLDLcell. Investigation into the
mechanism of action suggested that the ability of -
tocopherol to maintain EC membrane fluidity in the nor-
mal range was essential for the preservation of migration in
oxLDL.
METHODS
Preparation and modification of lipoproteins. LDL
(d  1.019-1.063) was isolated by sequential ultracentrif-
ugation from freshly drawn, citrated normolipemic human
plasma to which EDTA was added prior to ultracentrifuga-
tion.8 The purity was assessed by gel electrophoresis, and all
preparations were assayed for protein, total cholesterol
(Boehringer Mannheim Corp, Indianapolis, Ind), endo-
toxin (Pierce Chemical Co, Rockford, Ill), and TBARSs by
using the method of Schuh et al.9 TBARSs, one measure of
lipid oxidation, were expressed as nanomoles malondialde-
hyde (MDA) per milligram cholesterol. Immediately prior
to use, LDL was dialyzed against saline at 4°C for 48 hours
to remove the EDTA. Three different methods of oxidizing
LDL were used, two using activated monocytic (U937)
cells and one using CuSO4.
To prepare cell-modified LDL, Dacron- or zymosan-
activated U937 cells (American Type Culture Collection,
Rockville, Md) were used. Dacron graft material used to
activate U937 cells was prepared as previously described.10
Briefly, Cooley Double Velour Knitted Dacron Graft
(Meadox Medicals, Inc, Oakland, NJ) was cut into pieces
measuring 1.25  1.25 cm and weighing 80  5 mg;
sequentially washed in 10 mmol/L EDTA, buffer, ethanol,
and deionized water; and then plasma-sterilized. LDL ox-
idized by Dacron-activated U937 cells (oxLDLDac) was
prepared by combining a Dacron graft piece, LDL (1000
g), and U937 cells (500,000) in 1 mL RPMI (that
contains no added transition metal ions) and incubating for
24 hours, then centrifuging to remove graft fibers and
cellular debris. The supernatant was analyzed for choles-
terol recovery and TBARSs. Cell-modified LDL using zy-
mosan (from Saccharomyces cerevisiae; Sigma Chemical Co,
St. Louis, Mo) to activate the U937 cells (oxLDLzym) was
prepared similarly, replacing graft material with 4 mg zy-
mosan prepared as described by Ehrenwald et al.11
OxLDLCu was prepared by incubating 1 mL LDL (5-8
mg cholesterol/mL) with 1 mol/L CuSO4 for 16 to 24
hours at 37°C until the clear yellow solution became col-
orless. Oxidation was terminated by addition of 5 mol/L
EDTA. OxLDLCu was analyzed for TBARSs prior to use.
EC culture and migration assay. ECs from adult
bovine aortas were isolated by gentle scraping after colla-
genase exposure and subcultured in Dulbecco modified
Eagle medium and Ham F12 Nutrient Mixture (DMEM/
F12, 1:1, vol/vol) containing 5% fetal bovine serum (FBS).
ECs were used between passages 5 and 17.
EC migration was measured using a “razor scrape”
assay as previously described.1,12 ECs were grown to con-
fluence in 12-well tissue culture plates, made quiescent by
incubation in serum-free DMEM containing 0.1% gelatin
for 24 hours before use. To begin the migration assay, a
razor blade was pressed into the plastic to mark the starting
line, and cells on one side of the mark were removed with
the blade. Cells were washed, and colorless RPMI 1640
medium with 0.1% gelatin and test compound was added.
Migration was terminated at 24 hours by fixing with mod-
ified Wright-Giemsa stain. A 256-gray level, 640  480
pixel image of cells was captured with a digital charged-
coupled device camera mounted on a phase-contrast micro-
scope. Migration was measured by a semi-automated com-
puter-assisted procedure in which the number of cells that
crossed the starting line was determined in two randomly
selected fields, each 1500 m wide, in every well. All
experiments were performed in triplicate with at least two
different LDL preparations and two different cell isolates.
Results were expressed as the mean number of migrating
cells per 3000 m of starting line  SEM.
Protein synthesis measurement. Cell-associated pro-
tein synthesis was determined by measuring [3H]leucine
incorporation into trichloroacetic acid (TCA)-precipitable
material as previously described.13 Briefly, ECs were incu-
bated with [3H]leucine for 24 hours, lysed, and protein
precipitated with chilled 5% TCA. The precipitate was
solubilized, and radioactivity was determined in a scintilla-
tion counter and expressed as the percentage of applied
[3H]leucine incorporated into TCA-precipitable material
 1000.
Fluorescence recovery after photobleaching. ECs
were seeded at a density of 40,000/cm2 in DMEM/F12
with 5% FBS, allowed to adhere for 24 hours, made quies-
cent in serum-free DMEM/F12 for 18 hours, and then
incubated in RPMI 1640 medium with 0.1% gelatin. After
3 hours of treatment with agonist, the ECs were washed,
labeled with 1-acyl-2-(N-4-nitrobenzo-2-oxa-1,3 dia-
zole)-amino-caproyl phosphatidylcholine (a fluorescent
phospholipid analogue; Molecular Probes, Eugene, Ore)
during a 20-minute incubation at 37°C, and then tested for
fluorescence recovery after photobleaching (FRAP).14 A
small area of a cell (1-2m in diameter) was photobleached
with a 75-millisecond pulse of an argon laser (488 nm,
100% power) through a 40 long working distance objec-
tive of an ACAS-570 interactive laser cytometer (Meridian
Instruments, Inc, Okemos, Mich). Recovery of fluores-
cence within the bleached area, because of lateral diffusion
of neighboring unbleached fluorophore, was assessed by
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repetitive scanning across the cell surface with an attenu-
ated laser beam (30% power) at 488 nm for 90 seconds.
Rate and extent of recovery reflected relative membrane
microviscosity. Twenty to thirty individual measurements
were made for each test condition. Mean values with SEM
were calculated. ECs from three different isolates, and LDL
from three separate preparations were used to verify
findings.
Statistics. All data represent the mean SEM. Exper-
iments were performed in triplicate with at least three
different cell isolates. Data evaluation was performed by t
test or analysis of variance by using GraphPad InStat
(GraphPad Software, Inc, San Diego, Calif). Differences
were considered statistically significant at P  .05.
RESULTS
Effect of oxLDLDac on EC migration. The effect of
OxLDLDac and OxLDLCu on EC migration was com-
pared. Both OxLDLDac and oxLDLCu (TBARS, ranging
from 3 to 7 nmol MDA/mg cholesterol) caused nearly
complete inhibition of EC migration that was statistically
significant (Fig 1, A-B). Native LDL, which was not signif-
icantly oxidized (TBARS, ranging from 0.2 to 0.7 nmol
MDA/mg cholesterol), did not inhibit EC migration and,
in fact, stimulated migration. To determine whether other
factors from the graft material, or secreted by graft-acti-
vated U937 cells, inhibited EC migration, medium incu-
bated with Dacron graft material and LDL, or medium
incubated with Dacron graft material and U937 cells, was
also tested. In no case was EC migration inhibited (Fig 1,
A-B), suggesting that the LDL modified by Dacron-acti-
vated monocytes was responsible for the inhibition of EC
migration.
To assure that inhibition of EC migration by oxLDLDac
and oxLDLCu was not due to cytotoxicity or death, protein
synthesis and reversibility of the inhibition of EC migration
were examined. No significant change in protein synthesis
was noted between ECs treated with medium alone, native
LDL, oxLDLDac, or oxLDLCu (data not shown), suggest-
ing that cell injury and/or death was not responsible for the
decrease in movement. Reversibility of the inhibition was
demonstrated by resumption of EC movement following
removal of oxLDLDac or oxLDLCu 24 hours after initiation
of the migration assay (Fig 1, C). Migration during the
second 24-hour period, with no oxLDLDac or oxLDLCu
present, was not significantly different from the movement
of untreated ECs during a 24-hour period, indicating that
inhibition of migration by both forms of oxidized LDL was
reversible.
Antioxidant protection of EC migration. The oxi-
dative stress caused by oxLDL is postulated to be respon-
sible for inhibition of migration. If this is the mechanism,
antioxidants should restore migration. To assess this the-
ory, ECs were preincubated for 1 hour in -tocopherol
(vitamin E), probucol, or butylated hydroxytoluene
(BHT), which have been reported to protect ECs from
oxidative stress.15-17 EC migration in the presence of ox-
LDLDac or oxLDLCu and the antioxidant was measured
after 24 hours. Vitamin E consistently preserved EC migra-
tion in oxLDLDac, but neither probucol nor BHT was
protective (Fig 2, A-B). None of the tested antioxidants
preserved migration in oxLDLCu (Fig 2, C-D), despite
Fig 1. Inhibition of EC migration by oxLDLDac. EC migration
assay was performed with native LDL (400 g cholesterol/mL;
TBARS, 0.4), LDL incubated with Dacron graft material (400 g
cholesterol/mL; TBARS, 1.1), conditioned medium from U937
cells incubated with Dacron graft material, oxLDLDac (400 g
cholesterol/mL; TBARS, 3.7), or oxLDLCu (400 g cholesterol/
mL; TBARS, 3.8). Results are shown in pictorial form (A) and
graphic form (B). The reversibility of the inhibition of migration
was assessed by removing oxLDL after 24 hours, replacing me-
dium with RPMI 1640 with 0.1% gelatin, allowing migration to
proceed for an additional 24 hours, and then measuring EC
movement by image analysis (C). *P  .001 versus EC migration
in medium. #P .05 versus EC migration at 24 hours in medium.
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similar degrees of oxidation for oxLDLDac and oxLDLCu,
TBARSs of 8.0 and 6.6 nmol MDA/mg cholesterol, re-
spectively. -Tocopherol (50 mol/L) was capable of pre-
serving EC migration over a wide range of concentrations
of oxLDLDac (Fig 3, A). Increasing concentrations of
-tocopherol up to 200mol/L were incapable of protect-
ing EC migration in the presence of oxLDLCu (Fig 3, B).
Furthermore, the use of EDTA and CuSO4 to oxidize the
LDL did not account for -tocopherol’s inability to pre-
serve migration in oxLDLCu, because the addition of sim-
ilar quantities of EDTA and CuSO4 to oxLDLcell did not
alter the preservation of EC migration by -tocopherol
(data not shown). Another antioxidant vitamin, ascorbic
acid, did not preserve EC migration in oxLDL and did not
augment the effect of -tocopherol (data not shown).
These data suggested that the antioxidant properties of
-tocopherol did not account for its ability to preserve EC
migration in oxLDLDac.
Effect of zymosan-activated U937 cell-modified
LDL on EC migration. To determine whether other forms
of oxLDLcell had properties similar to oxLDLDac, the effect of
oxLDLzym on EC migration was studied. OxLDLzym signifi-
cantly inhibited EC migration (Fig 4, A), whereas superna-
tant collected from preparations of zymosan incubated with
medium alone, with U937 cells alone, or with LDL alone
did not inhibit EC migration. This finding confirmed that
oxLDL, not compounds within the zymosan preparation
or secreted by the cells in response to zymosan, was respon-
sible for inhibition of EC migration. The inhibition of
migration was reversible with removal of the oxLDLzym
(Fig 4, B), as previously noted with oxLDLDac and
oxLDLCu. -Tocopherol preincubation consistently pre-
served EC migration in oxLDLzym but not oxLDLCu (Fig
4, C). These results suggested that oxLDLcell, generated by
Dacron- or zymosan-activated monocytic cells, had prop-
erties distinct from oxLDLCu.
Preloading with -tocopherol preserves migra-
tion. The requirement for -tocopherol’s presence in the
medium during the migration assay was assessed. ECs were
preloaded with -tocopherol for 1 hour prior to initiation
of the migration assay. In only half of the wells was -
tocopherol replaced after the razor scrape and addition of
oxLDLDac. Migration was preserved with equal efficacy
when -tocopherol was preloaded only or when it was also
Fig 2. Vitamin E preserves EC migration in oxLDLDac. Confluent, quiescent ECs were preincubated with 50 mol/L
vitamin E, 40 mol/L probucol, or 10 mol/L BHT for 1 hour. Migration was then initiated in the presence of
antioxidant and 400 g/mL oxLDLDac (TBARS, 8.0) or oxLDLCu (TBARS, 6.6). Medium alone or native LDL
(TBARS, 0.7) served as control. The number of ECs migrating across the starting line at 24 hours was quantitated.
Results with oxLDLDac are shown in pictorial form (A) and graphic form (B). Results with oxLDLCu are shown in
pictorial form (C) and graphic form (D). *P .001 versus EC migration in medium. #P .05 versus EC migration in
medium.
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present during the 24-hour migration assay. This finding
suggested that the effect of vitamin E was on the cell rather
than on the lipoprotein in the medium.
Membrane fluidity changes. In addition to antioxi-
dant properties, -tocopherol has membrane-stabilizing
effects that result from incorporation of -tocopherol
into cell membranes. Therefore, the changes in the
relative membrane fluidity of ECs because of oxLDLDac,
oxLDLzym, and oxLDLCu, in the presence and absence
of -tocopherol, was studied. All three forms of oxidized
LDL significantly increased relative membrane fluidity
when compared with ECs in medium alone (Fig 5). These
results were confirmed with anisotropy measurements (data
not shown). When ECs were preincubated with -tocoph-
erol prior to addition of the various forms of oxLDL,
changes in relative membrane fluidity were prevented only
in ECs exposed to oxLDLDac and oxLDLzym, the two
cell-modified LDLs. ECs incubated in -tocopherol prior
to exposure to oxLDLDac or oxLDLzym had no statistically
significant difference in FRAP measurements compared
with ECs incubated in medium alone. However, relative
membrane fluidity was increased by oxLDLCu even in ECs
preincubated with -tocopherol. When -tocopherol and
native LDL alone were added to ECs, membrane fluidity
decreased slightly from control levels, consistent with pre-
vious findings.18
DISCUSSION
OxLDL has been the focus of many investigations
because of its potential role in the initiation and progression
of atherosclerotic lesions. In vitro studies of oxLDL’s effect
on cellular function have used LDL modified by a variety of
methods, most commonly LDL oxidized with transition
metal ions such as copper or iron. Although oxLDLcell is
more relevant to conditions in vivo, few investigations have
compared the effect of oxLDLCu and oxLDLcell on specific
cellular functions. Our studies demonstrate for the first
time that oxLDLcell inhibits EC migration and are consis-
tent with previous reports that iron- and copper-oxidized
LDLs inhibit EC migration.1,2 The more surprising finding
is that -tocopherol preserves migration of ECs incubated
in oxLDLcell but not in oxLDLCu. The inability of -to-
copherol to restore migration in the presence of oxLDLCu
is consistent with a previous report,2 but the finding that
-tocopherol preserves migration in the presence of
oxLDLcell is novel.
Antioxidants retard the formation of oxLDL and the
development of neointimal hyperplasia after balloon injury
in animal models, but their effects on cell function is not
fully defined. The antioxidants used in this study, BHT,
probucol, and -tocopherol, have been shown to protect
ECs from oxidative stress.15-17 BHT and probucol are
synthetic, whereas -tocopherol is the major lipid-soluble
antioxidant present in human plasma. -Tocopherol can
act as a peroxyl radical scavenger and break the chain
reaction associated with lipid peroxidation. BHT, another
chain-breaking antioxidant, does not preserve migration,
suggesting that other characteristics of -tocopherol are
responsible for its protective effect. -Tocopherol interca-
lates into cell membranes, and its location in the EC mem-
brane might contribute to its effectiveness. Probucol, how-
ever, has also been shown to be incorporated into the EC
membrane where it can act as a radical scavenger,16 so
simple intramembrane location of the antioxidant is un-
likely to account for the effectiveness of -tocopherol.
Membrane microviscosity is a critical determinant of
cell migration. Ghosh et al18 show a biphasic migratory
response to changes in membrane microviscosity. A mod-
erate decrease in membrane fluidity increases EC migra-
tion, but greater decreases inhibit migration. However,
increases in membrane fluidity also inhibit migration.
Fig 3. Effectiveness of vitamin E over a range of oxLDL concen-
trations. Confluent, quiescent bovine aortic ECs were preincu-
bated in 50 mol/L vitamin E for 1 hour, and then migration was
initiated in the presence of vitamin E and varying concentrations of
oxLDLDac (TBARS, 4.5; A)or oxLDLCu (TBARS, 4.4; B). At
maximal inhibition of EC migration by oxLDLCu, higher concen-
trations of vitamin E were also examined. *P  .001 versus EC
migration in medium. #P  .05 versus EC migration in medium.
**P .001 versus EC migration in same concentration of oxLDL
without vitamin E.
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Changes in membrane microviscosity are known to influ-
ence the function of membrane-bound proteins. Increased
membrane fluidity markedly decreases membrane-bound
Rac, a member of the Rho-GTPase (guanosine triphos-
phatase) family that regulates polymerization of actin in the
protrusion of lamellipodia necessary for migration.18 Al-
tered physical properties of the membrane can also directly
influence cytoskeletal function and lamellipodial exten-
sion.19 The present study shows that both oxLDLCu and
oxLDLcell increase membrane fluidity and inhibit EC mi-
gration.
The ability of -tocopherol to preserve EC migration in
oxLDLcell could be the result of optimization of membrane
fluidity. Vitamin E intercalates into cell membranes, de-
creases membrane fluidity, and abrogates lysophosphatidyl-
choline (lysoPC)-induced changes in microviscosity.18
However, probucol, despite being incorporated into the
cell membrane, has not been shown to possess any EC
membrane-stabilizing activity, as a result of steric and
charge considerations. This finding could account for the
difference in effectiveness of vitamin E and probucol in
preserving EC migration.
Fig 4. OxLDLzym inhibits EC migration. EC migration assay was performed with RPMI medium containing 0.1%
gelatin, medium exposed to zymosan for 24 hours, conditioned medium from U937 cells incubated with zymosan for
24 hours, LDL incubated with zymosan (400 g cholesterol/mL; TBARS, 0.9), or LDL incubated with zymosan and
U937 cells resulting in oxLDLzym (400 g cholesterol/mL; TBARS, 6.7). EC migration was quantitated by image
analysis at 24 hours (A). The reversibility of the inhibition by oxLDLzym was assessed in a parallel set of wells by
removing oxLDLzym after 24 hours, adding fresh medium without oxLDL, and quantitating migration after an
additional 24 hours. Migration during the 24 hours after removal of oxLDL was not significantly different than 24-hour
migration in medium alone (B). To determine the effectiveness of vitamin E in preserving EC migration in the presence
of oxLDLzym, cells were preincubated in vitamin E (50 mol/L) for 1 hour. Migration was initiated, and varying
concentrations of oxLDLzym or oxLDLCu (TBARS, 3.0) were added with vitamin E (50 mol/L). In control wells, no
vitamin E was added before or after initiation of the razor scrape assay. Migration was assessed after 24 hours (C). *P
 .001 versus EC migration in medium. #P  .05 versus EC migration in medium.
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Interestingly, preincubation with -tocopherol abro-
gates the increase in EC membrane fluidity in oxLDLcell
but not in oxLDLCu, and this finding parallels the preser-
vation of migration. The similarity of TBARS of the oxLDLCu
and oxLDLcell and the concentration range of -tocopherol
used suggest that neither LDL oxidation level nor insufficient
vitamin E explains the differences observed. Furthermore,
ECs are enriched with -tocopherol prior to incubation with
oxLDL, so equivalent amounts of -tocopherol would be
incorporated into the cell membranes. Boissonneault et al2
suggest that the inhibitory substance in oxLDLCu is not an
oxidized lipid. Studies in our laboratory indicate that the
components of oxLDL that inhibit EC migration reside in
the lipid fraction, and one is lysoPC.1 With the use of
thin-layer chromatography, we have shown that oxLDLCu
and oxLDLcell contain similar amounts of lysoPC (data not
shown). Furthermore, -tocopherol preserves EC migra-
tion in lysoPC.18 Thus, differences in lysoPC content of
oxLDLCu and oxLDLcell do not explain our observations.
Apparently, oxLDLCu contains multiple moieties that alter
membrane microviscosity, some of which are absent from
oxLDLcell, and their effects are not counteracted by -to-
copherol contained in the membrane.
Maintenance of membrane integrity by -tocopherol
could prevent activation of other systems that affect migra-
tion. Protein kinase C (PKC) activity is altered by physical
properties of the membrane,20 and -tocopherol inhibits
PKC activation by oxLDL.15 PKC reportedly stimulates
EC migration,21 so it is unlikely to represent the mecha-
nism by which vitamin E preserves migration. -Tocoph-
erol also decreases monocyte superoxide production by
inhibiting the assembly of nicotinamide adenine dinucle-
otide phosphate (NADPH) oxidase in the membrane22 and
might prevent deleterious effects of excess superoxide pro-
duction by ECs in oxLDL. Further investigations are re-
quired to clarify the mechanism by which -tocopherol
preserves migration.
Observational studies have correlated increased con-
sumption of dietary antioxidants with a reduced incidence
of cardiovascular disease,23-25 supporting the “oxidized
lipid” hypothesis of atherosclerosis, but prospective ran-
domized studies have not proven the efficacy of -tocoph-
erol (reviewed in Kaul et al26 and Vivekananthan et al27). In
a meta-analysis of seven large randomized trials of vitamin
E treatment, no improvement in all-cause mortality was
found in subjects taking vitamin E.27 Most of these studies,
however, focused on secondary prevention. Only two were
considered primary prevention trials, but those trials en-
rolled older patients or patients with risk factors for athero-
sclerosis.28,29 Results of the Cambridge Heart Antioxidant
Study did show a benefit by a reduction in nonfatal myo-
cardial infarctions.25 The timing of antioxidant initiation
could be important because the observational studies sug-
gesting a striking benefit were primary prevention trials in
subjects with no documented cardiovascular disease.23,24
Furthermore, dietary antioxidants were effective in reduc-
ing transplant atherosclerosis when therapy was started
within 2 years after cardiac transplantation.30
The mechanism of action of dietary antioxidants, in-
cluding -tocopherol, is thought to be reduction of the
Fig 5. Effect of oxLDLcell and oxLDLCu on membrane fluidity. ECs were incubated with native LDL (TBARS, 0.2),
oxLDLDac (TBARS, 6.6), oxLDLzym (TBARS, 6.3), or oxLDLCu (TBARS, 6.3) for 3 hours. In parallel wells, ECs were
preincubated with vitamin E (50 mol/L) for 1 hour prior to the addition of oxLDLDac, oxLDLzym, or oxLDLCu for
3 hours. The fluorescent phospholipid analogue was added, and then fluorescence recovery was measured after laser
photobleaching. *P  .05 versus recovery by ECs in medium. The statistical difference between recovery in oxLDL
with or without vitamin E preincubation is shown in the boxed insets.
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oxidizability of lipids and lipoproteins, but studies to date
have not documented the oxidative stress or the effective-
ness of antioxidants in reducing oxidizability of lipids in a
given patient. This lack of documentation is particularly
important because -tocopherol, although effective in
blocking free metal ion-catalyzed oxidation reactions in
vitro, does not efficiently block oxidation pathways (eg,
nitration, myeloperoxidase-catalyzed chlorination, oxida-
tive cross-linking) known to be operative in the atheroscle-
rotic artery wall.31-37 In a recent study, no reduction in
plasma F2-isoprostane levels (arachidonic acid oxidation
products that serve as markers of global oxidative stress)
was observed in subjects receiving -tocopherol supple-
mentation at five times normal doses (2000 IU/d  16
weeks).38 Those results suggest the need to critically assess
current “antioxidant” regimens, monitoring oxidative
stress in vivo and the ability of antioxidants to counteract
the oxidative stress to rigorously test the oxidation hypoth-
esis for atherosclerosis in humans.
Vitamin E has a number of properties in addition to its
antioxidant capacity that can promote optimal cellular
function. -Tocopherol can intercalate into cell mem-
branes and maintain membrane integrity. Our studies sug-
gest that oxLDLcell increases EC membrane fluidity and
inhibits migration in vitro, and the ability of -tocopherol
to preserve EC migration is dependent on the prevention of
these oxLDLcell-induced changes. A better understanding
of the mechanisms involved will allow development of
strategies to preserve cellular function and promote healing
of endothelial injuries in vivo.
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